Results 31 to 40 of about 17,756 (247)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells

Oncoimmunology, 2023
Chimeric antigen receptor (CAR)-T cells have not made significant progress in the treatment of acute myeloid leukemia (AML) in earlyclinical studies. This lack of progress could be attributed in part to the immunosuppressive microenvironment of AML, such
Xin Jin, Danni Xie, Rui Sun, Wen-Yi Lu, Xia Xiao, Yibing Yu, J. Meng, Ming-Feng Zhao   +7 more
semanticscholar   +1 more source

Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML

Blood, 2023
Introduction CAR-T efficacy in AML has been limited by a lack of ideal target antigens as well as the aggressive and resistant nature of disease. CD123 expression on leukemic blasts has been observed in about 80% of AML patients.
M. Wermke, Stephan Metzelder, S. Kraus, E. Sala, V. Vučinić, Walter Fiedler, K. Wetzko, Jonas A. Schäfer, M. Goebeler, J. Koedam, K. Franke, Matti Vänskä, A. Ehninger, M. Cartellieri, G. Ehninger, Tapan Maniar   +15 more
semanticscholar   +1 more source

Blastic plasmacytoid dendritic cell neoplasm in a young female: Rare and challenging

Indian Journal of Medical and Paediatric Oncology, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic malignancy with an aggressive behavior, seen commonly in the elderly age group and usually involves the skin.
Ketan Modak, Jeevan Kumar Garg, Deepak Kumar Mishra, Vivek S Radhakrishnan   +3 more
doaj   +1 more source

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +1 more source

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy

Journal of Experimental Medicine, 2023
This work demonstrates that engineering a single amino acid substitution into the cell surface protein CD123 in hematopoietic stem cells protects them from targeted immunotherapies.
Romina Marone, E. Landmann, Anna Devaux, R. Lepore, Denis Seyres, Jessica Zuin, T. Burgold, Corinne Engdahl, Giuseppina Capoferri, Alessandro Dell'Aglio, Clément Larrue, F. Simonetta, Julia Rositzka, M. Rhiel, G. Andrieux, Danielle N. Gallagher, Markus S. Schröder, Amélie Wiederkehr, A. Sinopoli, Valentin Do Sacramento, Anna Haydn, Laura Garcia-Prat, Christopher Divsalar, Anna Camus, Li-Wen Xu, Lorenza Bordoli, T. Schwede, M. Porteus, J. Tamburini, Jacob E. Corn, T. Cathomen, T. Cornu, Stefanie Urlinger, L. Jeker   +33 more
semanticscholar   +1 more source

Development of Astatine-211 ( 211 At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

, 2021
Background: Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia. Of current interest are alpha-particle emitting radionuclides as they deliver a very large amount of radiation over just a few cell diameters, enabling ...
Walter, Roland B., Orozco, Johnnie J., Wilbur, D. Scott, Green, Damian J., Lunn, Margaret C., Dexter, Shannon L., Hamlin, Donald K., O'Steen, Shyril, Laszlo, George S., Kehret, Allie R., Comstock, Melissa C.   +10 more
core   +1 more source

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia

Journal of Hematology & Oncology, 2022
Background Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy.
S. Caruso, B. De Angelis, F. del Bufalo, Roselia Ciccone, S. Donsante, Gabriele Volpe, S. Manni, M. Guercio, Michele Pezzella, L. Iaffaldano, D. A. Silvestris, M. Sinibaldi, S. Di Cecca, A. Pitisci, E. Velardi, P. Merli, M. Algeri, M. Lodi, Valeria Paganelli, M. Serafini, M. Riminucci, F. Locatelli, C. Quintarelli   +22 more
semanticscholar   +1 more source

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia

Haematologica, 2009
We evaluated CD123 expression in 95 pediatric and 24 adult ALL patients and compared the results with the CD123 expression in normal B-cell precursors.
Miroslav Djokic, Elisabet Björklund, Elisabeth Blennow, Joanna Mazur, Stefan Söderhäll, Anna Porwit   +5 more
doaj   +1 more source

Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia

European Journal of Haematology, 2023
The treatment of refractory and recurrent acute myeloid leukaemia (AML) is still a challenge with poor response rates and short survival times. In an attempt to solve this problem, we constructed a tandem bispecific chimeric antigen receptor (CAR ...
Xiangyang Wang, Mei-Ru Bian, G. Lin, Lei Yu, Yan-Ming Zhang, Depei Wu   +5 more
semanticscholar   +1 more source

Novel CD123 Binders for CAR-T Cell Therapy [PDF]

, 2020
CD123- the a-chain of the IL-3 cytokine receptor (IL3RA)- is a promising new immunotherapeutic target due to its surface expression on a multitude of leukemic disorders and possible link to proliferative advantage.
Parekh, Farhaan
core   +1 more source